Skip to content

Comparison of PRP (platelet-rich plasma) and PRF (platelet-rich fibrin) intraarticular injections in knee osteoarthritis.

Comparison of PRP (platelet-rich plasma) and PRF (platelet-rich fibrin) intra-articular injection in controlling the signs and symptoms of patients with knee osteoarthritis.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20250424065458N1
Enrollment
70
Registered
2025-07-26
Start date
2026-02-20
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

knee osteoarteritis. Osteoarthritis of knee

Interventions

Intervention 1: Autologous PRP will be prepared using a standardized two-step centrifugation protocol to ensure reproducibility and consistency. From each participant, 20 mL of peripheral venous blood
the remaining upper plasma will be discarded as platelet-poor plasma (PPP). Platelet and leukocyte counts will be measured from both baseline whole blood and final PRP samples using an automated hemat

Sponsors

Iran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to No maximum

Inclusion criteria

Inclusion criteria: mild to moderate knee osteoarthritis (stages of 2 and 3 based on Kellgren- Lawrence scale) Both sexes Aged = 45 years No severe swelling or inflammation of the knee joint or recent severe knee trauma within the past month. One or both knees affected, with injection will perform only for one eligible knee based on patient choice

Exclusion criteria

Exclusion criteria: no cooperation with researcher use of NSAID one week before or after injection or use of corticosteroid related drugs one month before and after injection technical problems which impair preparation of appropriate samples of PRP or PRF such as sample blood clotting before injection uncontrolled diabetes anemia ( hemoglobin less than 11 for females and less than 12 for males) thrombocytopenia ( less than 100000) malignancy skin infection

Design outcomes

Primary

MeasureTime frame
Pain based on visual analog scale. Timepoint: 1,3, 6, and 12 months. Method of measurement: Visual analog scale questionnaire.;Loss of knee range of motion. Timepoint: 1,3, 6, and 12 months. Method of measurement: gunya.;Functional impairment. Timepoint: 1,3, 6, and 12 months. Method of measurement: Western Ontario and McMaster Universities Osteoarthritis Index questionnaire.;Quality of life. Timepoint: 1,3, 6, and 12 months. Method of measurement: The 36-Item Short Form Survey (SF-36) questionnaire.

Secondary

MeasureTime frame
Knee osteoarthritis grade. Timepoint: before intervention and one year after intervention. Method of measurement: The Kellgren and Lawrence grading system ( plain knee radiography).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahram Mohaghegh

Iran University of Medical Sciences

shahrammohaghegh5@gmail.com+98 21 8895 3406

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026